Background-Both gemcitabine and etoposide are active in the treatment of small-cell lung cancer (SCLC), and are characterised by mild toxicity profiles. The combination of both drugs was found to be feasible and active in a phase I dose-finding study in solid tumours. Therefore, a phase II trial was initiated to examine the activity and toxicity of this schedule in extensive disease SCLC.
Introduction
Small-cell lung cancer (SCLC) accounts for approximately 15%-20% of all lung cancers [1] [2] [3] . It differs from non-small-cell lung cancer in its aggressive course and early dissemination in the absence of treatment. At the time of presentation, about one third of the patients will have limited disease (LD, i.e., not spread beyond one hemi-thorax), while two thirds will have extensive disease (ED) [3] .
Randomised studies have demonstrated the superiority of multi-drug regimens over single-agent therapy, with four to six courses of cisplatin and etoposide (PE) now being the standard regimen for most patients, irrespective of the stage at presentation [4] . In LD-SCLC, concurrent treatment with PE and thoracic irradiation has yielded the best survival rates so far [5, 6] .
.In ED-SCLC, a response rate to combination chemotherapy of 60%-80% can be expected, resulting in a median survival of 8-10 months, compared with 6-8 weeks for untreated patients [3, 7] . However, eventually virtually all patients will have a refractory relapse, and long-term survival is a very rare occurrence [7] . Chemotherapy in ED-SCLC is not curative, but can provide major palliative benefit: alleviation of superior vena cava syndrome, improvement of bronchial obstruction, pleural effusion, pain, or symptoms related to distant metastases. When the goal of treatment is palliative, however, the toxicity of cisplatin is a matter of concern, since advances in supportive care have not solved the problems of delayed emesis, renal toxicity and cumulative neuropathy. More recent data have suggested that the use of carboplatin (a derivative of cisplatin associated wkh less non-haematological toxicity), instead of cisplatin, is equally effective in ED-SCLC, but that the role of carboplatin needs further investigation in limited-stage SCLC [8, 9] .
Gemcitabine has proven to be an important drug in the palliative chemotherapy of advanced NSCLC [10] [11] [12] [13] , but has been tested far less extensively in SCLC. In previously untreated patients with ED-SCLC, gemcitabine monotherapy yielded a response rate of 27% [14] .
Etoposide, a topoisomerase II inhibitor, is one of the most active agents in SCLC, both as single agent and in combination with other agents [7, 15] .
Because of the activity and mild toxicity profile of both gemcitabine and etoposide, the combination of both drugs for the palliative treatment of ED-SCLC is appealing. A phase I dose-finding study in solid tumours showed the maximum tolerated dose (MTD) for this combination to be 1000 mg/m 2 gemcitabine, administered on days 1, 8 and 15, and 80 mg/m 2 etoposide administered on days 8, 9 and 10 of a 28-day cycle [16] .
Based on these results, a prospective phase II trial was initiated to investigate the efficacy and toxicity of the above schedule in the treatment of ED-SCLC.
Patients and methods

Patients
Patients were eligible if they met the following inclusion criteria, aged > 18 years, pathologically confirmed ED-SCLC: no prior chemotherapy; prior radiation therapy was allowed as long as the irradiated area was not the only source of measurable disease; no other forms of cancer therapy for at least three weeks prior to enrolment into the study; a Karnofsky performance status (KPS) >60, bi-dimensionally measurable disease; a life expectancy of at least 12 weeks; adequate bone marrow reserves as defined by an absolute neutrophil count (ANQ > I 5 x IO 9 /I, platelets > 100 x IO 9 /1. haemoglobin > 10 g/dl, adequate renal function, defined as creatinine clearance of ^ 60 ml/min. Exclusion criteria were: active infection; inadequate liver function; CNS metastases, serious concomitant systemic disorder incompatible with the study: a current second primary malignancy. The study was conducted in accordance with Good Clinical Practice guidelines and the declaration of Helsinki. Written informed consent was obtained from all patients.
Treatment schedule
Gemcitabine and etoposide were both administered on an outpatient basis: gemcitabine 1000 mg/m 2 intravenously over 30-60 minutes on days 1, 8 and 15. and etoposide 80 mg/m 2 intravenously over 30-60 minutes on days 8, 9 and 10. A four-week (28 days) schedule defined one cycle of therapy for both drugs. This schedule was chosen so that the nadir in terms of haematological toxicity occurred during the rest week.
Patient monitoring
No more than two weeks prior to study entry, each patient underwent the following evaluations: complete blood cell count (CBC), blood chemistries, urinalysis. temperature, ECG, vital signs and performance status.
During treatment, patients were assessed by physical examination at every visit, and for temperature, pulse and blood pressure before and after each infusion. A CBC was performed once a week together with a toxicity evaluation by the WHO grading system [17] . A blood chemistry was done every four weeks, and an ECG every eight weeks. All patients who received at least one dose of study drug were evaluated for toxicity and safety.
Efficacy was assessed by measurement of tumour size pre-treatment and at eight-week intervals by chest X-ray, chest CT, or other appropriate radiological imaging methods. Responses were evaluated using WHO criteria [18] All patients who had completed at least one cycle of therapy were evaluated for response. Responses had to be assessed based on measurable lung lesions in all patients. As for metastatic sites, only the lesions qualified for bi-dimensional measurement were recorded.
Therapy was continued until a patient's best response was obtained. Treatment was discontinued in the case of progressive disease or unacceptable toxicity, when the physician thought that this was in the best interest of the patient, or upon patient request. The use of second-line therapy was left at the discretion of the investigator.
Dose reductions
Dose adjustments for gemcitabine and etoposide within a cycle were made based on ANC and platelet counts, and WHO non-haematologlcal toxicities. Gemcitabine and etoposide were reduced to 75% for an ANC of 1.0-1. /I, respectively, treatment was put on hold.
Gemcitabine and etoposide were reduced to 50% or put on hold for WHO gTade 3 non-haematological toxicities. and put on hold subject to the opinion of the physician and the nature of the toxicity for all WHO grade 4 non-haematological toxicities.
Dose adjustments for gemcitabine were based on toxicity evaluations made on days 1, 8 and 15. For etoposide, dose adjustments made within cycle were based on evaluations made on day 8. Etoposide toxicity emerging on day 15 resulted in an etoposide dose reduction in the subsequent cycle.
Dose adjustments for subsequent cycles were made as follows: 50% dose reductions were made for febrile neutropenia, WHO grade 4 thrombocytopenia or thrombocytopenia with bleeding. Dose escalation after reduction was allowed if the reduced dosage was well tolerated. The criteria for non-haematological toxicities were as described above.
New cycles of treatment were resumed only after complete recovery from haematological toxicity, otherwise treatment was postponed for one week. If the delay was longer than two weeks, therapy was discontinued.
Endpoints and statistics
The primary study endpoint was the objective response rate. Secondary endpoints were the time-to-response, the duration of response, the toxicity, and the time-to-progression (TTP) and survival using Kaplan-Meier estimations.
The study was designed to enrol at least 40 patients. Based on the 'null hypothesis' that the response rate for the gemcitabine-etoposide combination is 30%, this sample size allowed detection of response rates of 49% with a power of 0.8.
The duration of response in responding patients was measured from the time of the initial administration of gemcitabine until disease progression. TTP was measured from administration of the first gemcitabine dose until disease progression. Survival was measured from administration of the first dose of gemcitabine until the date of death or the date of the last patient contact for censored cases.
Results
Patients
Forty-two patients, thirty-one males and eleven females, were enrolled into this multi-centre, single-arm phase II study. The median age of the patients at study entry was 59.5 years (range 41-84) ( Table 1) . The majority of patients had a KPS of ^ 80%. No patient had received prior chemotherapy. All patients received at least one dose of gemcitabine. 
Efficacy
Five patients (11.9%) were not eligible for efficacy analysis due to insufficient therapy (less than one cycle of treatment). No complete responses (CR) and 17 partial responses (PR) were obtained in the 37 evaluable patients, yielding an overall response rate of 46% (95% confidence interval (CI): 29-63) ( Table 2 ). The median time to response was 1.8 months (95% CI: 0.9-1.9). The median duration of response was 5.8 months (95% CI: 3.8-8.6). Ten patients (27%) had disease stabilisation, while six (16%) had progressive disease (PD). In four patients (11%) the response could not be assessed. One patient died after the first cycle due to pre-existing angina pectoris that was judged by the investigator not to be study drug related. One patient discontinued therapy after the first cycle due to disturbance of a pre-existing diabetes mellitus and another discontinued therapy after the second cycle due to peritonitis. Both events were assessed by the investigator not to be study drug related. Finally, one patient died after the first cycle due to study drug related neutropenic sepsis. Fifteen of the qualified patients (40.5%) discontinued treatment due to a lack of efficacy (progressive or stable disease), one (2.7%) due to personal patient decision, and four (10.8%) due to satisfactory response as assessed by the physician (PR). Nine patients (24.3%) discontinued treatment for clinical relapse after a previous PR. Secondline therapy consisted of symptom controlling radiotherapy in nine patients, and various types of secondline chemotherapy at the discretion of the investigator in suitable patients.
The median survival of the 37 protocol qualified patients was 10.5 months (95% CI: 7.5-12.0) and the medianTTP was 3.7 months (95% CI: 2.1-5.0). Seventyeight percent of patients were alive at six months and thirty-seven percent at twelve months (Figure 1 ).
Dose reductions and to.xicitv
The number of completed cycles was 126, with a mean number per patient of 3 (range 0-6). Of the 386 planned gemcitabine doses, 36 (9.3%) were reduced and 13 (3.4%) were omitted. The primary causes of these dose reductions and omissions were leukopenia and thrombocytopenia. The mean and median dose intensities of gemcitabine were 908.4 mg/m 2 and 985.5 mg/m 2 , respectively. Of the 384 planned etoposide doses, 13 (3.4%) were reduced and 9 (2.3%) were omitted. The primary causes of the etoposide dose reductions and omissions were also leukopenia and thrombocytopenia. The mean and median dose intensities of etoposide were 76.6 mg/m 2 and 80.0 mg/m 2 , respectively. Patients received on average 97% of their planned gemcitabine dose and 98% of their planned etoposide dose.
All 42 patients received at least one dose of chemotherapy and were evaluated for toxicity. Five (11.9%) withdrew from the study due to adverse events: one patient each due to diabetes mellitus, dyspnea, leukopenia, peritonitis and rash. Six patients (14.3%) died during the study: three due to progressive disease and one each from angina pectoris, heart failure and neutropenic sepsis caused by myelosuppression. Only the last occurrence was thought to be treatment related, as stated previously. At the time of this event, the ICPS of this patient had decreased to 50%, a weight loss of 10% was noted, and the investigator did not omit the day 15 gemcitabine dose, despite a white blood cell and neutrophil count of 1.09 and 0.2 x 10 9 /l, respectively.
The WHO laboratory toxicities are summarised in Table 3 . There were 36 grade 3 and 27 grade 4 haematological/laboratory toxicities. Red blood cell transfusions were administered in case of anaemia with important co-morbidity or symptoms, or haemoglobin values below 8 g/dl. Fourteen patients (33.3%) had one ore more red blood cell transfusions. Four patients (9.5%) had platelet transfusions.
Non-laboratory toxicities are listed in Table 4 . There were 28 instances of grade 3 toxicity. Three grade 4 non-laboratory toxicities occurred (cutaneous, oral and infection) in three different patients.
Discussion
The outpatient combination of gemcitabine 1000 mg/m 2 administered intravenously over 30-60 minutes on days 1, 8 and 15, and etoposide 80 mg/m 2 administered intravenously over 30-60 minutes on days 8, 9 and 10, of a 28-day cycle, achieved an objective response rate of 46% in the 37 protocol qualified patients, with ED-SCLC, enrolled in this phase II multi-centre study. Moreover, 27% of the patients experienced disease stabilisation. The median duration of response was 5.8 months and the median survival 10.5 months. In addition, the toxicity was mild and manageable and nearly all the planned doses of both agents could be administered.
The combination of cisplatin and etoposide (EP), despite the increased use of carboplatin-based chemotherapy, is still generally considered to be the treatment of choice for patients with SCLC [3, 4] . In LD, this combination, given concurrently with radiotherapy, has yielded the most attractive results available to date [5, 6] . In ED, this schedule has also been studied thoroughly.
In order to improve the results in patients with ED-SCLC, different strategies such as dose escalation, alternating non-cross-resistant chemotherapy, maintenance chemotherapy, or weekly intense chemotherapy, have been evaluated. None of these strategies have had a clear impact on the prognosis. When higher than standard doses were administered, there was no evidence of a better treatment outcome [19] [20] [21] . The initially favourable data obtained using alternating EP and cyclophosphamide-doxorubicin-vincristine (CAV) [22] , based on the hypothesis of non-cross-resistance, could not be confirmed in two large-scale trials [23, 24] . Maintenance chemotherapy could perhaps increase the duration of the initial remission, but the prolonged toxicity of the therapy was not justified by any change in long-term treatment outcome [25] . Very recently, the concept of weekly intense chemotherapy, based on the previous Japanese data with the cyclophosphamide-vincristinedoxorubicin-etoposide (CODE) regimen, did not prove to be worthwhile in a large NCI-C/SWOG study [26] . Despite all these efforts of the last decade, refractory relapse still leads to treatment failure in virtually all ED-SCLC patients.
It must be clear that chemotherapy thus remains a palliative option in the treatment of ED-SCLC, and in this setting, new treatment options that try to avoid the cumbersome toxicity of platinum are appealing. Therefore, it was decided to initiate this phase II study with a combination of gemcitabine plus etoposide, previously proven to be feasible and active in a phase I study of patients with various solid tumours [16] . Gemcitabine with its novel mechanism of action and modest toxicity profile indeed seemed a good partner for combination with etoposide.
Although the response rate in this multi-centre phase II trial was a little lower than expected with standard platinum-based chemotherapy, the results for TTP and median survival time compare favourably with previous reports on CAV [22] [23] [24] , EP [23, 24] or other palliative options such as the all-oral multi-drug regimen of etoposide and cyclophosphamide [27] .
The results of the present study are also associated with a favourable toxicity profile, especially in terms of non-haematological toxicity. The haematological toxicity, however, was more pronounced than anticipated based on the haematological toxicity profiles of these drugs when used as single agents. Severe (grade 3 and 4) haematological toxicity occurred in 40% of the patients for neutropenia, and in 22% for thrombocytopenia (Table 3) . In contrast to platinum-based regimens, the incidence of severe non-laboratory toxicity with the gemcitabine-etoposide schedule was remarkably low. Grade 3 and 4 nausea/vomiting was present in only 12.2% of the patients, while other grade 3 and 4 toxicities were isolated findings (Table 4 ). Of particular interest are the low occurrence of severe infectious complications (14.6%), and the absence of severe peripheral neurotoxicity or renal toxicity.
In its present form, the regimen is cumbersome for the patients, because of the frequent outpatient administrations, but this is in part balanced by mild toxicity. The use of oral in stead of iv etoposide in this regimen might greatly increase patient convenience. This would probably not jeopardise the activity of the combination. A retrospective analysis has even suggested that oral delivery of etoposide in combination with cisplatin is associated with increased survival when compared with i.v. etoposide delivery [28] . Now that the activity and mild toxicity profile has been confirmed, the use of oral instead of i.v. etoposide could be investigated, to reduce the number of outpatient administration days. Another potentially interesting way ahead could be the combination of cisplatin-etoposide plus gemcitabine. According to preliminary date, this combination is feasible and a suggested schedule for phase II studies has been determined [29] .
We conclude that the present phase II study demonstrates that this combination of gemcitabine plus etoposide in patients with ED-SCLC, resulted in a lower response rate, a median survival time comparable to the one obtained with standard platinum-based regimens, but with lower levels of grade 3 and 4 toxicity. Thus, this combination, which can be administered on an outpatient basis, provides a very reasonable palliative option for ED-SCLC.
